Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 21, 2019
Reporting Period: Events occurring between August 8, 2019, and August 23, 2019.
Context: The filing details unregistered sales of equity securities, specifically the repayment of promissory notes, issuance of new convertible notes, and conversion of debt into common stock.
Key Financial Metrics
This filing does not provide comprehensive financial statements (revenue, profit, cash flow, or margins). It reports specific capital transaction metrics:
- Debt Repayment: $328,733 (inclusive of accrued interest and prepayment premiums) repaid between August 15 and August 16, 2019.
- New Debt Issuance: $750,250 in principal amount of convertible promissory notes issued between August 8 and August 20, 2019.
- Cash Proceeds: $694,500 received from the new convertible notes.
- Debt-to-Equity Conversion: $80,271 of outstanding indebtedness (inclusive of interest) converted into 682,562 shares of common stock between August 16 and August 23, 2019.
- Interest Rate: New notes bear interest at 12% per annum.
Material Changes
The filing reports significant changes in the company's capital structure during the reporting period:
- Net Debt Position: The company reduced existing debt by $328,733 while simultaneously increasing debt obligations by $750,250 in principal, resulting in a net increase in debt principal of approximately $421,517 before accounting for the debt-to-equity swap.
- Equity Dilution: The issuance of 682,562 shares of common stock to settle $80,271 of debt represents a material increase in outstanding shares.
- Liquidity: The company generated $694,500 in cash proceeds from the new note issuance.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or strategic commentary beyond the description of the transactions.
Risks and Contingencies:
- Conversion Terms: New notes are convertible at a fixed price of $1.00 or $2.00 per share for the first six months. Thereafter, the conversion price is generally 58% of the fair value of the stock, which may lead to significant future dilution if the stock price rises.
- Regulatory Compliance: The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for exemptions from registration, asserting that investors are accredited and no general solicitation was used.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion to assess dilution impact.
- Confirm the specific conversion price ($1.00 vs. $2.00) applicable to each of the new notes issued.
- Review the company's cash balance to determine if the $694,500 proceeds are sufficient to cover operating expenses until the August 2020 maturity of the new notes.
- Check subsequent filings for any further debt conversions or defaults on the new 12% interest-bearing notes.